Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
SEPTIN2 DIFF6, KIAA0158, NEDD5, SEPT2
Sequence Length (AA) Molecular Weight (Da)
361 41487
Protein Name
Septin-2
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MSKQQPTQFI NPETPGYVGF ANLPNQVHRK SVKKGFEFTL MVVGESGLGK
60 70 80 90 100
STLINSLFLT DLYPERVIPG AAEKIERTVQ IEASTVEIEE RGVKLRLTVV
110 120 130 140 150
DTPGYGDAIN CRDCFKTIIS YIDEQFERYL HDESGLNRRH IIDNRVHCCF
160 170 180 190 200
YFISPFGHGL KPLDVAFMKA IHNKVNIVPV IAKADTLTLK ERERLKKRIL
210 220 230 240 250
DEIEEHNIKI YHLPDAESDE DEDFKEQTRL LKASIPFSVV GSNQLIEAKG
260 270 280 290 300
KKVRGRLYPW GVVEVENPEH NDFLKLRTML ITHMQDLQEV TQDLHYENFR
310 320 330 340 350
SERLKRGGRK VENEDMNKDQ ILLEKEAELR RMQEMIARMQ AQMQMQMQGG
360 361
DGDGGALGHH V

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for non-CPTAC-6126 Collapse assay details

Data source: Panorama

Official Gene Symbol
SEPTIN2
Peptide Sequence
VNIVPVIAK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
175
Peptide End
183
CPTAC ID
non-CPTAC-6126
Peptide Molecular Mass
951.6117
Species
Homo sapiens (Human)
Assay Type
Direct MRM-MS
Matrix
Bovine Serum Albumin
Submitting Laboratory
McGill University
Submitting Lab PI
Christoph H. Borchers, Gerald Batist

Publication

View Details (opens in a new window)

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Agilent 6495B QQQ-MS
Internal Standard
Standard Isotope labeled internal standard peptides with 13Cx, 15Ny (R+10 or K+8)
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Infinity 1290
Column Packing
commercial (Agilent ZORBAX Eclipse Plus C18)
Column Dimensions
4.6 mm × 150 mm, (5 µm)
Flow Rate
0.4 mL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b2 (1+) 6.8 4.5 7.4 8.5 5.9 5.4 10.9 7.4 9.2 16 16 17
b3 (1+) 7.1 6.1 5.6 7.5 4.9 4.1 10.3 7.8 6.9 16 16 17
y5 (1+) 3.2 6.7 6.1 7.3 5.8 5.2 8 8.9 8 16 16 17
y6 (1+) 6.8 8.5 7.5 7.3 8.2 7.9 10 11.8 10.9 16 16 17
y7 (1+) 7.2 5.3 6 9.3 7.5 6.1 11.8 9.2 8.6 16 16 17
sum 2.2 2.5 2.2 2.8 2.8 3.1 3.6 3.8 3.8 16 16 17


Stability

Data source: Panorama

Fragment ion / Transition control_intra_CV actual_temp_intra_CV frozen_intra_CV FTx1_intra_CV FTx2_intra_CV
b2 (1+) 8.4 9.3 7.8 3.5 8.9
b3 (1+) 4.3 3 3.4 3.1 2.6
y5 (1+) 7.8 3.9 4.9 6.2 3.1
y6 (1+) 7.3 4 6.7 4.9 5.3
y7 (1+) 5.6 5.4 8.9 2.1 4.5
sum 2.3 2.9 3.2 1.3 4
Fragment ion / Transition all_intra_CV all_inter_CV
b2 (1+) 7.9 8.4
b3 (1+) 3.2 5.7
y5 (1+) 5 4.3
y6 (1+) 5.4 4
y7 (1+) 5.3 6.4
sum 2.8 2.6

Endogenous

Data source: Panorama

Fragment ion / Transition intra_CV inter_CV total_CV
b2 (1+) 7.3 24.4 25.5
b3 (1+) 16.9 28.9 33.5
y5 (1+) 2.8 14.2 14.5
y6 (1+) 4.8 19.1 19.7
y7 (1+) 20.7 26.9 33.9
sum 5.4 19 19.8

Additional Resources and Comments